Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease - ACR Meeting Abstracts
![PDF] Therapeutic Potency of Febuxostat for Hyperuricemia in Patients with Chronic Kidney | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f8f35c9a28527099688c8822dfc437c8d7c15701/2-Table1-1.png "PDF] Therapeutic Potency of Febuxostat for Hyperuricemia in Patients with Chronic Kidney | Semantic Scholar")
PDF] Therapeutic Potency of Febuxostat for Hyperuricemia in Patients with Chronic Kidney | Semantic Scholar
Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study - Yang - 2022 -
Frontiers | Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective,
Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study - Yang - 2022 -
Lesson: Gout and Hyperuricemia: Treatment Update and Pharmacist's Role
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
PDF) Febuxostat in patients with hyperuricemia and severe chronic kidney disease
Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study | SpringerLink
Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction | Hypertension Research
Adherence to allopurinol dosing guidelines | Download Table
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial - ScienceDirect
Febuxostat Dosage Guide + Max Dose, Adjustments - Drugs.com
Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD Sarvepalli PS, Fatima M, Quadri AK, Taher AR, Habeeb A, Amreen F, Parveen BN, Rajaram K G -
Study design. Febuxostat dose 40 or 80 mg; verinurad dose range 2.5-20 mg. | Download Scientific Diagram
Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD Sarvepalli PS, Fatima M, Quadri AK, Taher AR, Habeeb A, Amreen F, Parveen BN, Rajaram K G -
Treatment Update For Gout The Future is Now - ppt download
Febuxostat - wikidoc
Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression | PLOS ONE
A Review of Hyperuricaemia Management with Febuxostat: Dosage Titration, Monitoring and Maintenance
Pharmaceuticals | Free Full-Text | Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
Variations of serum uric acid and febuxostat dose across different... | Download Scientific Diagram
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease - ACR Meeting Abstracts
Variations of serum uric acid and febuxostat dose across different... | Download Scientific Diagram
Febuxostat administration for the prevention of tumour lysis syndrome: A meta‐analysis - Bellos - 2019 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease | Scientific Reports
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management | NEJM Evidence
